# Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

> **NCT03514017** · PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 5 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03514017
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-31
- **Primary completion:** 2023-05-16
- **Final completion:** 2023-05-16
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Funding unavailable
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03514017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03514017, "Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03514017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*